The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats

Journal of Surgical Research

Volumn 66, Issue 2, 1996, Pages 147-153

  Chen, Han Ming ^a   Hwang, Tsang Long ^a   Chen, Miin Fu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ASPARTATE AMINOTRANSFERASE; CERULETIDE; GABEXATE MESILATE; GLYCODEOXYCHOLIC ACID; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEMATOCRIT; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER BLOOD FLOW; MALE; MICROCIRCULATION; NONHUMAN; PANCREAS BLOOD FLOW; PANCREATITIS; PRIORITY JOURNAL; RAT;

EID: 0030498765     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0387     Document Type: Article

References (26)

1. 1. Zweifach, B. W. Vitalism revisited - An historical perspective of microcirculatory concepts. Int. J. Microcirc. Clin. Exp. 14: 91, 1994.
2. 2. Bockman, D. E. Microvasculature of the pancreas: Relationship to pancreatitis. Int. J. Pancreatol. 12: 11, 1992.
3. 3. Kusterer, K., Enghofer, M., Zendler, S., Blochle, C., and Usadel, K. H. Microcirculatory changes in sodium taurocholate-induced pancreatitis in rats. Am. J. Physiol. 260: G346, 1991.
4. 4. Bassi, D., Kollias, N., Fernandez-del Castillo, C., et al. Impairment of pancreatic microcirculation correlates with the severity of acute experimental pancreatitis. J. Am. Coll. Surg. 179: 257, 1994.
5. 5. Kelly, D. M., McEntee, G. P., McGeeney, K. F., et al. Microvasculature of pancreas, liver, and kidney in cerulein-induced pancreatitis. Arch. Surg. 128: 293, 1993.
6. 6. Ward, P. A. Mechanism of endothelial cell injury. J. Lab. Clin. Med. 118: 421, 1991.
7. 7. Trapnell, J. E., Rigby, C. C., and Talbot, C. H. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br. J. Surg. 61: 177, 1974.
8. 8. Case, A. G. Death from acute pancreatitis: MRC multicenter trial of glucagon and aprotinin. Lancet 22: 632, 1977.
9. 9. Harada, H., Miyake, H., Ochi, K., Tanaka, J., and Kimura, I. Clinical trial with protease inhibitor gabexate mesilate in acute pancreatitis. Int. J. Pancreatol. 9: 75, 1991.
10. 10. Buchler, M., Malferteiner, P., Uhl, W., Scholmerich, J., Stokmann, F., Adler, G., Rolle, K., Ditschuneit, H., and Beger, H. G. Gabexate mesilate in human acute pancreatitis: Results from the German multicentric trial with 4 gr/day. Digestion 46: 130, 1990.
11. 11. Tamura, Y., Hirado, M., Okamura, K., Minamoto, Y., and Fujii, S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim. Biophys. Acta 484: 417, 1978.
12. 12. Freise, J., Schmidt, F. W., Magerstedt, P., and Schmid, K. Gabexate mesilate and camostate: New inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. Clin. Biochem. 18: 224, 1985.
13. 13. Kosaki, G., Nomura, T., and Kambayashi, J. The mechanism of the inhibitory effect of proteinase inhibitors on platelet aggregation and cellular synthesis of prostaglandins. Thromb. Res. 19: 579, 1980.
14. 14. Zimmerman, B. J., Gaginella, T. S., and Granger, D. N. Effects of SC-41930 on leukocyte adherence and emigration in rat mesenteric venules. Agents Actions 37: 80, 1992.
15. 15. Sporman, H., Sokolowski, A., and Letko, G. Effect of temporary ischemia upon development and histological patterns of acute pancreatitis in the rat. Pathol. Res. Pract. 184: 507, 1989.
16. 16. Friess, H., Weber, A., and Buchler, M. Standards in monitoring acute experimental pancreatitis. Eur. Surg. Res. 24(Suppl. 1): 1, 1992.
17. 17. Hirano, T., Manabe, T., and Tobe, T. Protective effects of gabexate mesilate (FOY) against impaired pancreatic energy metabolism in rat acute pancreatitis induced by caerulein. Life Sci. 49(22): PL179, 1991.
18. 18. Tanaka, N., Tsuchiya, R., and Ishii, K. Comparative clinical study of FOY and Trasylol in acute pancreatitis. Adv. Exp. Med. Biol. 1208: 367, 1979.
19. 19. Yang, C. Y., Chang-Chien, C. S., and Liaw, Y. F. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 2(6): 698, 1987.
20. 20. Valderrama, R., Perez-Mateo, M., Navarro, S., Vazquez, N., Sanjose, L., Adrian, M. J., and Estruch, J. Multicenter double-blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 51(2): 65, 1992.
21. 21. Takemoto, Y., Tanaka, S., Tanabe, J., Nakamura, Y., Kohama, A., and Shibata, S. Studies on the effects of primary therapy for DIC following circulatory arrest. Am. J. Hematol. 21: 377, 1986.
22. 22. Pederzoli, P., Cavallini, G., Falconi, M., and Bassi, C. Gabexate mesilate vs aprotinin in human acute pancreatitis: A prospective, ramdomized, double-blind multicentric study. Int. J. Pancreatol. 14: 117, 1993.
23. 23. Taeneka, N., Shimada, Y., Kawai, M., Yoshiya, I., and Kosaki, G. Survival from DIC following amniotic fluid embolism: Successful treatment with a serine proteinase inhibitor; FOY. Anesthesia 36: 389, 1981.
24. 24. Dobosz, M., Sledzinski, Z., Basinski, A., Stanek, A., Babicki, A., and Wajda, Z. Effect on hemodynamics of therapeutic infusion of gabexate mesilate (FOY) in experimental acute pancreatitis. Res. Exp. Med. 189(2): 77, 1989.
25. 25. Steinberg, W., and Tenner, S. Acute pancreatitis. N. Engl. J. Med. 330: 1198, 1994.
26. 26. Arfors, K. E., Rutili, G., and Svensjo, E. Microvascular transport of macromolecules in normal and inflammatory conditions. Acta Physiol. Scand. Suppl. 463: 93, 1979.